University of Calgary Researcher Has Provided New Study Findings on Liver Cancer (Atezolizumab + bevacizumab versus lenvatinib as first-line systemic therapy for treatment of hepatocellular carcinoma in a real-world population: Outcomes from...).

Předmět:	LIVER cancer ATEZOLIZUMAB BEVACIZUMAB RESEARCH personnel PROTEIN-tyrosine kinase inhibitors HEPATOCELLULAR carcinoma
Zdroj:	Immunotherapy Weekly; 7/9/2024, p1509-1509, 1p
Abstrakt:	A recent study conducted by researchers at the University of Calgary compared the effectiveness of two first-line systemic therapies for advanced hepatocellular carcinoma (HCC), a type of liver cancer. The study analyzed data from 453 patients who received either atezolizumab with bevacizumab (AB) or lenvatinib (LEN) as their first-line treatment. The results showed that patients treated with AB had a longer median overall survival (mOS) compared to those treated with LEN. However, progression-free survival (PFS) and response rate (RR) were similar between the two treatments. This study provides real-world evidence on the efficacy of AB compared to LEN in the treatment of HCC. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu